[生物书合集].Advances.in.Clinical.TBiostatisti

[生物书合集].Advances.in.Clinical.TBiostatisti

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
(1972,1975)andpresentedin(ChalonerandLarntz,1989).Once x hasbeen determined, random sampling without replacement can be used to deter- mine the dose level contained in x that is to be administered each patient in the next cohort. For cancer phase I trials, we typically seek to optimize the treatment of each individual patient. Attention might therefore focus on identifying a dose that all available evidence indicates to be the best estimate of the MTD. This is the basis for the continual reassessment method (CRM) proposed by O’Quigley et al. (1990). In the present context their original formulation can be described as follows. Let p ( ±j N ) denote the model selected for the dose-toxicity relationship parameterized in terms of N . Given the data from k patients, the probability of DLT at any permissible dose level x 2 S can be estimated as ˆ u k ð x Þ¼ Z H p ð x j u Þ C k ð u Þ d u or ˆ u k ð x p ð x j ˆ N k Þð 10 Þ where ˆ N k denotes an estimate of N . The next patient is then treated at the
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 06/13/2011 for the course PHYSICS 101 taught by Professor Shu during the Spring '11 term at FIU.

Ask a homework question - tutors are online